Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

102.39 -0.18 (-0.18%)
Streaming Delayed Price Updated: 10:13 AM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
38 39 Next >
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
Visualizing the World’s Biggest Pharmaceutical Companies
Some of the world’s biggest pharmaceutical companies have played a central role in the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life
Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617. With positive Phase 3 primary endpoint data in the bag, Novartis at the European... 
Via Benzinga
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-... 
Via Benzinga
What may be behind achy, tired, or burning eyes? Dry eye disease may be the culprit.
(BPT) - Sponsored by Novartis Pharmaceuticals Corporation. 
Via Brandpoint
Exposures COVID-19
Better Pharmaceutical Stock: Apellis or Novartis?
The pharmaceutical industry is expected to remain in the limelight as companies race to develop new medicines catering to mild diseases and critical ailments. 
Via Talk Markets
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. 
Via Talk Markets
Exposures COVID-19
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would... 
Via Benzinga
Exposures COVID-19
Regenerative Medicine Market Growing at a CAGR of 15.9% – Rising Demand for Organ Transplantations
The global regenerative medicine market is expected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9%. 
Via SBWire
Exposures Product Safety
Why Regenxbio Stock Is Way Up Today
American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration. 
Via The Motley Fool
ADHD Drug Developer Cingulate Plans NASDAQ Debut
Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Why Did Wedbush Downgrade Xoma?
Wedbush has cut XOMA Corporation (NASDAQ: XOMA) to neutral from outperform and lowered its price target to $22 from $41. Analyst Liana Moussatos notes ... 
Via Benzinga
DGTL is First Enabled to Convert and Distribute Social Media Influencer Content to Programmatic Web Ads
New York, New York--(Newsfile Corp. - September 7, 2021) - DGTL Holdings Inc. (TSXV: DGTL) (OTCQB: DGTHF) (FSE: A2QB0L) ("DGTL"... 
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novartis Stops Iscalimab Trial In Kidney Transplant Patients
Novartis AG (NYSE: NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients. The decision follows interim data that showed iscalimab was... 
Via Benzinga
Price Over Earnings Overview: Novartis
Looking into the current session, Novartis Inc. (NYSE:NVS) is trading at $92.23, after a 0.45% drop. Over the past month, the stock decreased by 0.02%, but over the... 
Via Benzinga
The Rising Delta Variant
China is not only cracking down on kiddie playtime. It also is absorbing bankruptcy claims from real estate developer Evergrande. 
Via Talk Markets
Topics Bankruptcy
Exposures Financial Legal
Coherra Continue to Add Strength to the Organization and Cap Table With the Appointment of Thomas Ebeling as a New Member of the Advisory Board
Coherra is strengthening its global business development ahead of the scaling phase with the appointment of Thomas Ebeling as Advisory Board Member. Thomas will be working with Coherra's founder, Søren... 
Via Newswire.com
Novartis, NHS England Ink Access Deal For Cholesterol Drug Leqvio
The U.K. government, NHS England, and Novartis AG (NYSE: NVS) unveiled a "world-first" reimbursement deal for providing broader access to anti-cholesterol... 
Via Benzinga
DGTL Holdings Inc. Reports the Completion of Software Development for Hashoff 2.0
New York, New York--(Newsfile Corp. - August 31, 2021) - DGTL Holdings Inc. (TSXV: DGTL) (OTCQB: DGTHF) (FSE: D0G) (WKN:... 
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
Vision Care Products Market Giants Spending Is Going to Boom with CooperVision, Essilor International S.A., Carl Zeiss Meditec
Vision Care Products Comprehensive Study by Type (Eye Glasses (Single Vision Eyeglasses, Bifocal Eyeglasses, Progressive Eyeglasses), Contact Lens (Personalized/Custom, Specific Care, Single Vision,... 
Via SBWire
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
UCB Gets EU Approval For Bimekizumab In Psoriasis
The European Commission has cleared UCB's (OTC: UCBJF) Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults. UCB's confidence lies in... 
Via Benzinga
Living with Chronic Hives: One Woman’s Story
(BPT) - Ilana, a board-certified emergency medicine physician, lived with chronic hives for almost as long as she can remember. 'I've had them since I was at least 8 years old,' she says. 'It's... 
Via Brandpoint
Exposures Product Safety
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Exposures COVID-19
Novartis' STAMP Inhibitor Under FDA Review For Myeloid Leukemia
The FDA has accepted for review Novartis AG's (NYSE: NVS) marketing application seeking approval for asciminib (ABL001) in chronic myeloid leukemia (CML).... 
Via Benzinga
Exposures Product Safety
Reuters Events Announces the Shortlist for the 12th Annual Responsible Business
SOURCE: Reuters Events Sustainable Business 
Via 3BL Media
Topics Emissions Stocks
Exposures COVID-19 US Equities
Only The Conservative Pot Stocks Index Is Up YTD And Currently Yields 4.9%
If you were to invest in a basket of the major companies that have bought into marijuana companies you could possibly generate greater returns than only owning the associated marijuana company. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Novartis's Kymriah Flunks In Late-Stage NHL Study
Novartis AG's (NYSE: NVS) Kymriah (tisagenlecleucel) CAR-T therapy failed to meet its primary endpoint of event-free survival in a Phase 3 study in aggressive... 
Via Benzinga
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the... 
Via Talk Markets
Exposures Product Safety
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.